HCW Biologics Inc.(HCWB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

HCWB HCW Biologics Inc.

Market Closed 12-20 16:00:00 EST

0.4490

+0.0360

+8.72%

盘后0.4400

-0.0090-2.00%

19:54 EST

High0.4500	Low0.3900	Vol367.08K
Open0.4006	D1 Closing0.4130	Amplitude14.53%
Mkt Cap18.85M	Tradable Cap9.88M	Total Shares41.98M
T/O158.34K	T/O Rate1.67%	Tradable Shares22.01M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"HCWB","market":"US","secType":"STK","nameCN":"HCW Biologics Inc.","latestPrice":0.449,"timestamp":1734728400000,"preClose":0.413,"halted":0,"volume":367080,"hourTrading":{"tag":"盘后","latestPrice":0.44,"preClose":0.449,"latestTime":"19:54 EST","volume":3023,"amount":1274.9116,"timestamp":1734742464324},"delay":0,"floatShares":22010000,"shares":41983394,"eps":-1.003073,"marketStatus":"Market Closed","change":0.036,"latestTime":"12-20 16:00:00 EST","open":0.4006,"high":0.45,"low":0.39,"amount":158337.909694,"amplitude":0.145278,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.003073,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734944400000},"marketStatusCode":7,"adr":0,"listingDate":1626753600000,"exchange":"NASDAQ","adjPreClose":0.413,"preHourTrading":{"tag":"盘前","latestPrice":0.3995,"preClose":0.413,"latestTime":"08:34 EST","volume":7403,"amount":2973.977208,"timestamp":1734701683829},"postHourTrading":{"tag":"盘后","latestPrice":0.44,"preClose":0.449,"latestTime":"19:54 EST","volume":3023,"amount":1274.9116,"timestamp":1734742464324},"volumeRatio":0.8708830679462568},"requestUrl":"/m/hq/s/HCWB/tweets","defaultTab":"tweets","newsList":[{"id":"2486829815","title":"HCW Biologics Secures Strategic Agreements and Funding to Propel Growth and Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2486829815","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486829815?lang=en_us&edition=fundamental","pubTime":"2024-11-27 20:55","pubTimestamp":1732712115,"startTime":"0","endTime":"0","summary":"Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on HCW Biologics (HCWB – Research Report). The associated price target i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/hcw-biologics-secures-strategic-agreements-and-funding-to-propel-growth-and-innovation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/hcw-biologics-secures-strategic-agreements-and-funding-to-propel-growth-and-innovation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","HCWB"],"gpt_icon":0},{"id":"2485288171","title":"HCW Biologics Expands with New Financial Agreements","url":"https://stock-news.laohu8.com/highlight/detail?id=2485288171","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485288171?lang=en_us&edition=fundamental","pubTime":"2024-11-21 05:56","pubTimestamp":1732139812,"startTime":"0","endTime":"0","summary":"HCW Biologics ( ($HCWB) ) has issued an announcement. HCW Biologics Inc. has entered a $6.9 million securities purchase agreement with an instituti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/hcw-biologics-expands-with-new-financial-agreements?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/hcw-biologics-expands-with-new-financial-agreements?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","HCWB","BK4539"],"gpt_icon":0},{"id":"2484500751","title":"HCW Biologics prices $6.9M registered direct offering at $1.03 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2484500751","media":"TipRanks","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484500751?lang=en_us&edition=fundamental","pubTime":"2024-11-20 14:55","pubTimestamp":1732085706,"startTime":"0","endTime":"0","summary":"HCW Biologics  “announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 6,717,000 shares of common stock in a registered direct offering priced above market under Nasdaq rules. In a concurrent private placement, the Company also agreed to issue unregistered warrants to purchase up to an aggregate of 6,717,000 shares of common stock. The combined effective offering price for each share of common stock and accompanying warrants is $1.03. The warrants will have an exercise price of $1.03 per share, will be exercisable immediately, and expire on the five year anniversary from the date of issuance.”Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks. Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter. HCW Biologics licenses proprietary preclinical molecule to WY Biotech","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/mZDcjNmmKhClNQkla1p5GA--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/d622151edd421d0d1465b02718e80caa","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/mZDcjNmmKhClNQkla1p5GA--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/d622151edd421d0d1465b02718e80caa"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/hcw-biologics-prices-6-9m-065506140.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hcw-biologics-prices-6-9m-065506140.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["HCWB","BK4139","BK4539"],"gpt_icon":0},{"id":"2484912334","title":"HCW Biologics to Raise $6.9 Million in Gross Proceeds From Direct Offering, Private Placement; Shares Extend Gains Premarket","url":"https://stock-news.laohu8.com/highlight/detail?id=2484912334","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484912334?lang=en_us&edition=fundamental","pubTime":"2024-11-19 19:28","pubTimestamp":1732015728,"startTime":"0","endTime":"0","summary":"HCW Biologics  disclosed late Monday an agreement for a single institutional investor to purchase about 6.7 million shares in a registered direct offering priced above market under Nasdaq rules.In a concurrent private placement, the company also agreed to issue unregistered warrants to purchase up to an aggregate of about 6.7 million shares.The combined effective offering price for each share and accompanying warrants is $1.03. The warrants will have an exercise price of $1.03 per share, be exercisable immediately, and expire five years after the issuance date.The gross proceeds from the registered direct offering and concurrent private placement are estimated to be about $6.9 million.The offering will likely close on or about Nov. 20.Shares of the company were up over 37% in premarket activity Tuesday after closing up 311% in regular trading on Monday.Price: 1.7100, Change: +0.47, Percent Change: +37.90","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","HCWB","BK4139"],"gpt_icon":1},{"id":"2484960086","title":"HCW Biologics announces pricing of $6.9M registered direct offering, concurrent private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2484960086","media":"seekingalpha","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484960086?lang=en_us&edition=fundamental","pubTime":"2024-11-19 15:00","pubTimestamp":1731999631,"startTime":"0","endTime":"0","summary":"nan_bkk/iStock via Getty Images  HCW Biologics  has entered into a securities purchase agreement with a single institutional investor to purchase 6.7M shares in a registered direct offering priced above market, the company said Monday after the bell. In a concurrent private placement, HCW Biologics  also agreed to issue unregistered warrants to purchase up to an aggregate of 6,717,000 shares of common stock.  The combined effective offering price for each share of common stock and accompanying warrants is $1.03. The warrants will have an exercise price of $1.03 per share, will be exercisable immediately, and expire on the five-year anniversary from the date of issuance. The gross proceeds to HCW Biologics  from the registered direct offering and concurrent private placement are estimated to be approximately $6.9 million. The offering is expected to close on or about November 20, 2024. HCWB +8.87% after hours to $1.35. Source: Press Release","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/518782500/image_518782500.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/518782500/image_518782500.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4305477-hcw-biologics-announces-pricing-of-69m-registered-direct-offering-concurrent-private-placement","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4539","BK4139","HCWB"],"gpt_icon":1},{"id":"2484495667","title":"BRIEF-Hcw Biologics Prices $6.9 Mln Registered Direct Offering And Concurrent Private Placement At $1.03 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2484495667","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484495667?lang=en_us&edition=fundamental","pubTime":"2024-11-19 10:29","pubTimestamp":1731983386,"startTime":"0","endTime":"0","summary":"BRIEF-Hcw Biologics Prices $6.9 Mln Registered Direct Offering And Concurrent Private Placement At $1.03 Per ShareNov 18 (Reuters) - HCW Biologics Inc HCWB.O:HCW BIOLOGICS ANNOUNCES PRICING OF $6.9 MI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241119:nTUA8WTW0T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","HCWB"],"gpt_icon":1},{"id":"2484956662","title":"HCW Biologics Inc - Combined Effective Offering Price Set at $1.03 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2484956662","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484956662?lang=en_us&edition=fundamental","pubTime":"2024-11-19 10:27","pubTimestamp":1731983268,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241119:nTUA8WTW0T:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HCWB","BK4139","BK4539"],"gpt_icon":0},{"id":"2484495665","title":"HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2484495665","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484495665?lang=en_us&edition=fundamental","pubTime":"2024-11-19 10:27","pubTimestamp":1731983268,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241119:nTUA8WTW0T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","HCWB"],"gpt_icon":0},{"id":"2484956992","title":"HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2484956992","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484956992?lang=en_us&edition=fundamental","pubTime":"2024-11-19 10:27","pubTimestamp":1731983220,"startTime":"0","endTime":"0","summary":"MIRAMAR, Fla., Nov.  18, 2024  (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and deve","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/19/2983249/0/en/HCW-Biologics-Announces-Pricing-of-6-9-Million-Registered-Direct-Offering-and-Concurrent-Private-Placement-Priced-Above-Market-Under-NASDAQ-Rules.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539",".IXIC","MNQmain","IE00BKPKM429.USD","IE00B3QW5Z07.USD","NDAQ","HCWB","IE00B64PRP62.GBP","LU2210150020.SGD","SQQQ","IE00BGHQF748.EUR","LU2210149790.SGD","TQQQ","BK4588","QID","PSQ","BK4585","QLD","BK4139","NQmain","BK4112","LU2095319765.USD"],"gpt_icon":1},{"id":"2484600534","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2484600534","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484600534?lang=en_us&edition=fundamental","pubTime":"2024-11-19 03:23","pubTimestamp":1731957806,"startTime":"0","endTime":"0","summary":"HCW Biologics  and WY Biotech said they struck a licensing deal to develop and commercialize one of the former's immunotherapeutic product candidates.Under the terms, HCW Biologics will receive a $7 million upfront payment from WY Biotech, and the latter will cover all expenses such as research and development, manufacturing, and clinical development, the companies said Monday.Shares catapulted 376% as intraday trading volume soared to more than 473.2 million from a daily average of about 49,000.Eco Wave Power Global  said Monday it received the final nationwide permit from the US Army Corps of Engineers for an energy project at AltaSea's premises at the Port of Los Angeles.Shares soared 37% as intraday trading volume advanced to more than 504,000 from a daily average of about 58,000.U.S. Gold  said its unit received final permit approval from the Wyoming Department of Environmental Quality air quality division, clearing the way for developing the CK gold project.Shares advanced 10% as","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4139","BK4168","HCWB","BK4133","USAU","WAVE"],"gpt_icon":0},{"id":"2484860146","title":"HCW Biologics Shares Surge on License Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2484860146","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484860146?lang=en_us&edition=fundamental","pubTime":"2024-11-19 02:07","pubTimestamp":1731953220,"startTime":"0","endTime":"0","summary":"HCW Biologics shares skyrocketed as the company entered a licensing agreement with China's WY Biotech for an immunotherapeutic product candidate.The stock had chalked up a seven-fold rise to $2.25 early Monday afternoon, on volume of more than 418 million shares, compared with a 65-day average of 48,629. The intraday high of $2.52 marks a 52-week peak and a recovery from Friday's 52-week low of 28 cents.HCW will receive a $7 million upfront payment and is eligible to receive additional milestone payments and double-digit royalties on future product sales.\"Our preclinical studies demonstrated that this multi-functional product candidate is highly effective at inducing anti-tumor CD8(+) T cell and NK cell responses without triggering unwanted side effects in relevant solid tumor animal models,\" HCW said.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","HCWB"],"gpt_icon":0},{"id":"2484674940","title":"Why Is Penny Stock HCW Biologics Surging On Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2484674940","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484674940?lang=en_us&edition=fundamental","pubTime":"2024-11-18 23:15","pubTimestamp":1731942901,"startTime":"0","endTime":"0","summary":"HCW Biologics Inc  stock is trading higher during Monday premarket with a strong session volume of 10.03 million versus an average volume of 48.02K, as per data from Benzinga Pro.HCW Biologics and WY Biotech Co., Ltd., a China-based company specializing in the early-stage development of recombinant protein drugs and gene/cell therapies, have entered into a worldwide exclusive license agreement.WY Biotech has agreed to pay HCW Biologics $7.0 million upfront. HCW Biologics is eligible to receive additional significant development milestone payments and double-digit royalties on future product sales.HCW Biologics also has a payment-free, milestone-free, and royalty-free option to recapture the development and commercialization rights of this molecule for the United States, Canada, Central America, and South America  after the conclusion of the Phase 1 clinical trial.WY Biotech is financially responsible for all costs associated with the molecule’s research and development, manufacturing, ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/X22.q.wW8UKTBMjA0O8ArA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/4461cf7d8c8702930159cb9cabf3469a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/X22.q.wW8UKTBMjA0O8ArA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/4461cf7d8c8702930159cb9cabf3469a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-penny-stock-hcw-biologics-151501847.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","BK4139","HCWB"],"gpt_icon":1},{"id":"2484362201","title":"HCW Biologics, WY Biotech Sign License Deal for Immunotherapeutic Product Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2484362201","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484362201?lang=en_us&edition=fundamental","pubTime":"2024-11-18 21:14","pubTimestamp":1731935678,"startTime":"0","endTime":"0","summary":"HCW Biologics  and WY Biotech said Monday they struck a license deal to develop and commercialize one of the former's immunotherapeutic product candidates.Under the terms, HCW Biologics will receive a $7 million upfront payment from WY Biotech, while the latter will cover all expenses regarding research and development, manufacturing, clinical development, regulatory approval, and commercialization of the candidate, the companies added.HCW Biologics will cover costs for clinical development, regulatory approval, and commercialization of the candidate in the US, Canada, Central America, and Latin America, the parties said.HCW Biologics shares surged 246% in recent Monday premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HCWB","BK4221","BK4139","BK4539","BK4084","BK4585","WY","BK4588"],"gpt_icon":0},{"id":"2484622184","title":"HCW Biologics jumps on license agreement for immunotherapeutic product candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2484622184","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484622184?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:12","pubTimestamp":1731931976,"startTime":"0","endTime":"0","summary":"sanjeri/E+ via Getty Images  U.S.-based HCW Biologics'  shares rallied in Monday's premarket trade, driven by a license, research and co-development agreement with China's WY Biotech for one of its new proprietary preclinical molecules. HCW Biologics  up +114.84% premarket to $0.64. Key terms of the","market":"other","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1131583289/image_1131583289.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1131583289/image_1131583289.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4301703-hcw-biologics-jumps-on-license-agreement-for-immunotherapeutic-product-candidate-with-wy-biotech","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["HCWB","SQQQ","BK4539","QID","PSQ","QLD","BK4139",".IXIC","NQmain","MNQmain","TQQQ"],"gpt_icon":0},{"id":"2484686626","title":"HCW Biologics and Wy Biotech Announce License Agreement  for Immunotherapeutic Product Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2484686626","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484686626?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:00","pubTimestamp":1731931227,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUA74DNHT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","HCWB","BK4539"],"gpt_icon":0},{"id":"2484680626","title":"HCW Biologics Inc - Is Eligible to Receive Additional Milestone Payments and Double-Digit Royalties on Future Product Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2484680626","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484680626?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:00","pubTimestamp":1731931227,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUA74DNHT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","HCWB"],"gpt_icon":0},{"id":"2484626612","title":"HCW Biologics Inc - to Receive $7 Million Upfront Payment","url":"https://stock-news.laohu8.com/highlight/detail?id=2484626612","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484626612?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:00","pubTimestamp":1731931227,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUA74DNHT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","HCWB"],"gpt_icon":0},{"id":"2484626446","title":"HCW Biologics and WY Biotech Announce License Agreement  for Immunotherapeutic Product Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2484626446","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484626446?lang=en_us&edition=fundamental","pubTime":"2024-11-18 20:00","pubTimestamp":1731931200,"startTime":"0","endTime":"0","summary":"HCW Biologics entered into License, Research and Co-Development Agreement with WY Biotech for one of its new proprietary preclinical molecules. HCW Biologics to receive upfront payment of $7 million and is eligible to receive additional milestone payments and double-digit royalties on future product sales. MIRAMAR, Fla., Nov. 18, 2024  -- HCW Biologics Inc. , , a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, and WY Biotech Co., Ltd., a China-based company specializing in the early-stage development of recombinant protein drugs and gene/cell therapies, announced today that they have entered into a worldwide exclusive license agreement to develop and commercialize one of HCWB’s product candidates generated with its new drug discovery platform for therapeutic use.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8l2snnK0b8ctrQOE1efX4g--~B/aD05MDE7dz0xODAxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/21d4872a3dbeeef33f6167b19b91e191","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8l2snnK0b8ctrQOE1efX4g--~B/aD05MDE7dz0xODAxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/21d4872a3dbeeef33f6167b19b91e191"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hcw-biologics-wy-biotech-announce-120000184.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","BK4139","HCWB","BK4084","WY","BK4585","BK4588","BK4221"],"gpt_icon":1},{"id":"2483635595","title":"HCW Biologics Q3 Sales $426.42K Down From $853.10K YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2483635595","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483635595?lang=en_us&edition=fundamental","pubTime":"2024-11-15 06:01","pubTimestamp":1731621687,"startTime":"0","endTime":"0","summary":"HCW Biologics (NASDAQ:HCWB) reported $426.42 thousand in sales this quarter. This is a 50.02 percent decrease over sales of $853.10 thousand the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41992962/hcw-biologics-q3-sales-426-42k-down-from-853-10k-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"HCW Biologics Q3 Sales $426.42K Down From $853.10K YoY","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCWB"],"gpt_icon":0},{"id":"2483353591","title":"HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2483353591","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483353591?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:40","pubTimestamp":1731620400,"startTime":"0","endTime":"0","summary":"MIRAMAR, Fla., Nov.  14, 2024  (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/14/2981674/0/en/HCW-Biologics-Reports-Third-Quarter-2024-Financial-Results-and-Business-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSQ","NQmain","BK4539","HCWB","QLD","MNQmain","SQQQ","BK4139","TQQQ","QID",".IXIC"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.hcwbiologics.com","stockEarnings":[{"period":"1week","weight":0.2577},{"period":"1month","weight":-0.526},{"period":"3month","weight":-0.2675},{"period":"6month","weight":-0.3789},{"period":"1year","weight":-0.6044},{"period":"ytd","weight":-0.6335}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. The company was incorporated in 2018 and is headquartered in Miramar, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.041883},{"month":2,"riseRate":0.666667,"avgChangeRate":0.076487},{"month":3,"riseRate":0.666667,"avgChangeRate":0.071795},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.107695},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.105877},{"month":6,"riseRate":0.666667,"avgChangeRate":0.049274},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.013489},{"month":8,"riseRate":0.25,"avgChangeRate":-0.119069},{"month":9,"riseRate":0.5,"avgChangeRate":-0.021114},{"month":10,"riseRate":0.25,"avgChangeRate":0.015667},{"month":11,"riseRate":0.25,"avgChangeRate":-0.169409},{"month":12,"riseRate":0.25,"avgChangeRate":-0.049741}],"exchange":"NASDAQ","name":"HCW Biologics Inc.","nameEN":"HCW Biologics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"HCW Biologics Inc.(HCWB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest HCW Biologics Inc.(HCWB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"HCW Biologics Inc.,HCWB,HCW Biologics Inc.股票,HCW Biologics Inc.股票老虎,HCW Biologics Inc.股票老虎国际,HCW Biologics Inc.行情,HCW Biologics Inc.股票行情,HCW Biologics Inc.股价,HCW Biologics Inc.股市,HCW Biologics Inc.股票价格,HCW Biologics Inc.股票交易,HCW Biologics Inc.股票购买,HCW Biologics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"HCW Biologics Inc.(HCWB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest HCW Biologics Inc.(HCWB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction